Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) connected to the company's US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding specific personnel transactions rather than a financial performance report.
Material Changes
The filing details a revaluation of the cash element of a notional investment held within the US Retirement Savings Plan, which is notionally held in GSK American Depositary Shares (ADSs). On January 4, 2013, an increase in the notional allocation of ADSs occurred at a price of $44.26 per ADS.
Management Commentary and Risks
Management commentary is limited to the notification of the plan administrators regarding the ADS allocation. The filing references compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c). No specific risks, contingencies, or unusual items regarding the company's broader operations are disclosed in this text.
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on January 4, 2013.
- Share Price: The ADS price used for the allocation was $44.26.
- Involved Parties:
- Dr M M Slaoui (Director): 18 ADSs
- Dr K Slaoui (Connected Person): 2 ADSs
- Mr W C Louv (Director): 7 ADSs
- Plan Context: These transactions relate to the US Retirement Savings Plan and are not direct market purchases by the individuals.